Evolving CAR T-Cell Therapy in Large B-Cell Lymphoma

Dr. Megan Melody introduces the program and welcomes Dr. Miguel Perales and Dr. Nirav Shah before framing the discussion around the evolving role of real-world evidence in large B-cell lymphoma (LBCL). Dr. Perales provides an overview of the current CAR T-cell therapy landscape, highlighting the three approved CD19-directed products, tisagenlecleucel, axicabtagene ciloleucel, and lisocabtagene maraleucel, and describing how their roles have expanded since the initial approvals in later-line relapsed or refractory disease. He reviews the evidence supporting the use of axicabtagene ciloleucel and lisocabtagene maraleucel in the second-line setting for patients with primary refractory disease or early relapse, noting the positive ZUMA-7 and TRANSFORM trials. He also discusses data in transplant-ineligible patients and highlights emerging real-world comparative evidence, including differences in efficacy and safety across products. The discussion sets the stage for examining how real-world evidence can complement pivotal clinical trial findings in LBCL.